Ep 169 The Tox Talks (Chapter 2): Alluzience/Liquid Abobotulinum | Dr Christoph Martschin

Episode 169 hosts Dr Christoph Martschin (Dermatologist based in Lisbon, Portugal) Christophe has been a Galderma KOL since 2011. As a global speaker and trainer, he has a wealth of knowledge when it comes to Galderma's portfolio and research projects.  In this mini series 'The Tox Talks', we feature expert injectors who have significant experience in using botulinum toxins. These episodes explore our guests experiences using particular brands, the evolution of their injecting techniques and we get special insights into the subtle nuances of getting the best out of toxins. In chapter 2 we focus on a newly launched brand called 'Alluzience', (Abobotulinum toxin A), a novel toxin developed by Galderma that is the world's first liquid toxin. 00:00 Introduction 01:03 Dr Christoph Martschin 04:55 Why Liquid Toxin Was Developed   10:59 How Alluzience Differs From Traditional Toxins   18:27 Faster Onset and Longer Duration Explained   26:25 Patient Demand for Convenience and Flexibility   33:29 Practical Benefits of Pre Diluted Toxin   41:37 Reducing Human Error and Improving Consistency   48:53 Sustainability and Reduced Clinical Waste   52:09 Managing Patient Expectations With Longer Duration   61:45 Pricing, Profitability and Clinic Workflow   68:49 Comfort During Injection and Treatment Experience   76:38 When to Use Different Toxin Options   80:09 Consultation Approach and Treatment Planning   86:34 Safety Profile and Real World Performance   90:43 Future of Neuromodulators and New Product Innovation ALL IA LINKS & CONTACT INFORMATION